Search | OpenScholar

Search results

1934 results found

The controversy concerning plasma homocysteine in Parkinson disease patients treated with levodopa alone or with entacapone: effects of vitamin status.

Publication: Journal Article

Zesiewicz, TA, L Wecker, KL Sullivan, LR Merlin, and RA Hauser. 2006. “The Controversy Concerning Plasma Homocysteine in Parkinson Disease Patients Treated With Levodopa Alone or With Entacapone: Effects of Vitamin Status.”. Clinical Neuropharmacology.

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington’s disease.

Publication: Journal Article

Zesiewicz, TA, KL Sullivan, RA Hauser, and J Sanchez-Ramos. 2006. “Open-Label Pilot Study of Levetiracetam (Keppra) for the Treatment of Chorea in Huntington’s Disease.”. Mov Disord.

Adenosine A2A receptor antagonists for Parkinson’s disease: rationale, therapeutic potential and clinical experience. Drugs Aging. 2005;22:471-482.

Publication: Journal Article

Hauser, RA, and MA Schwarzchild. 2005. “Adenosine A2A Receptor Antagonists for Parkinson’s Disease: Rationale, Therapeutic Potential and Clinical Experience. Drugs Aging. 2005;22:471-482.”. Drugs Aging.

Levetiracetam for the treatment of essential tremor. Movement Disorders 2005; 20:640.

Publication: Journal Article

Sullivan, KL, RA Hauser, and TA Zesiewicz. 2005. “Levetiracetam for the Treatment of Essential Tremor. Movement Disorders 2005; 20:640.”. Movement Disorders.

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Movement Disorders 2005;20:783-791.

Publication: Journal Article

Truong, D, DD Duane, J Jankovic, C Singer, LC Seeberger, CL Comella, MF Lew, et al. 2005. “Efficacy and Safety of Botulinum Type A Toxin (Dysport) in Cervical Dystonia: Results of the First US Randomized, Double-Blind, Placebo-Controlled Study. Movement Disorders 2005;20:783-791.”. Movement Disorders.

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 2004;61:561-566.

Publication: Journal Article

Group, Parkinson Study. 2004. “A Controlled, Randomized, Delayed-Start Study of Rasagiline in Early Parkinson Disease. Arch Neurol 2004;61:561-566.”. Arch Neurol.

Heart failure in Parkinson's disease: analysis of the United States medicare current beneficiary survey. Parkinsonism Relat Disord 2004;10:417-420.

Publication: Journal Article

Zesiewicz, TA, JA Strom, AR Borenstein, RA Hauser, CR Cimino, H Fontanet, C Cintron, JF Staffetti, PB Dunne, and KL Sullivan. 2004. “Heart Failure in Parkinson’s Disease: Analysis of the United States Medicare Current Beneficiary Survey. Parkinsonism Relat Disord 2004;10:417-420.”. Parkinsonism Relat Disord.

Botulinum toxin A for the treatment of cervical dystonia. Expert Opin Pharmacother 2004;5:2017-2024.

Publication: Journal Article

Zesiewicz, TA, W Stamey, KL Sullivan, and RA Hauser. 2004. “Botulinum Toxin A for the Treatment of Cervical Dystonia. Expert Opin Pharmacother 2004;5:2017-2024.”. Expert Opin Pharmcother.

Depression in Parkinson’s disease. Curr Psychiatry Rep 2002;4:69-73.

Publication: Journal Article

Zesiewicz, TA, and RA Hauser. 2002. “Depression in Parkinson’s Disease. Curr Psychiatry Rep 2002;4:69-73.”. Curr Psychiatry.

Bilateral human fetal striatal transplantation in Huntington’s disease. Neurology 2002;58:687-695.

Publication: Journal Article

Hauser, RA, S Furtado, CR Cimino, H Delgado, S Eichler, S Schwartz, D Scott, et al. 2002. “Bilateral Human Fetal Striatal Transplantation in Huntington’s Disease. Neurology 2002;58:687-695.”. Neurology.